Latest Posts

Author name: Lawrence Ganti

Lawrence Ganti is the Global President of Life Sciences, CEO of  Americas, and Member of the Global Executive Community. Prior to joining Innoplexus, Lawrence spent 15 years leading teams across functions and geographies in the pharmaceutical industry. He also worked as a research associate for McKinsey & Company and holds an MBA from IMD in Switzerland and a bachelors from Babson College in the United States.

Build KOL Connections and Leverage Their Networks to Influence Stakeholders

Key opinion leaders (KOLs) play a central role in creating brand value for a pharmaceutical company. They are not only the face of the brand for the outside world but also an irreplaceable resource within the company, bringing new insights and overall enhancement throughout the drug development process. So, who are the KOLs? When a …

Build KOL Connections and Leverage Their Networks to Influence Stakeholders Read More »

How can AI help in Transforming the Drug Development Cycle?

Artificial intelligence (AI) is transforming the pharmaceutical industry with extraordinary innovations that are automating processes at every stage of drug development. Pharma companies are investing in AI-driven applications for transforming healthcare, reducing R&D spends, and expanding the scope of drug discovery. By expediting research efforts, AI is turning hype into use cases and increasing ROI …

How can AI help in Transforming the Drug Development Cycle? Read More »

Can AI-Enhanced Data Analytics Accelerate Clinical Trials?

The success rate of clinical trials carries significant weight in the business of pharma. In addition to dedicating considerable time and effort, the industry spends billions on R&D every year. Clinical development requires optimal decision-making and multiple insights on various parameters, including identifying trial sites, recruiting patients, coordinating logistics, and overseeing research. Adding pressure to …

Can AI-Enhanced Data Analytics Accelerate Clinical Trials? Read More »

How AI Makes Identifying Biomarkers More Accurate and Efficient

Current approaches to drug development that rely solely on identifying statistical differences between healthy and diseased patients to pinpoint biomarkers, molecular targets, or suitable drugs often fail to provide biologically useful results. While these differences can help predict which patients are likely to have misregulation of a particular gene, receptor, or protein, the majority of …

How AI Makes Identifying Biomarkers More Accurate and Efficient Read More »

Leveraging AI to Optimize Clinical Trial Design and Site Enrollment

The request The client wanted help with clinical trial design and assistance with site selection, patient enrollment, and identification of suitable investigators. Background and challenges The client, a mid-sized pharmaceutical company, was entering phase II clinical trials for a drug targeting diffuse large B-cell lymphoma (DLBCL). However, due to limited prior experience clinically developing an …

Leveraging AI to Optimize Clinical Trial Design and Site Enrollment Read More »

Biotech’s Future Success Lies in Innovative Technology and Real-Time Data

Businesses that adapt to current innovations in technology are in a much better position to realize success than those that don’t. No company has ever been able to withhold innovation and thrive. Today, the biotechnology industry faces tremendous challenges, including unsuccessful projects, unexpected terminations, missed deadlines, and high expenditures. Those companies that embrace technological innovations …

Biotech’s Future Success Lies in Innovative Technology and Real-Time Data Read More »

Does Your Scientific Narrative Resonate in the Pharmaceutical Ecosystem?

Monitoring the impact of your scientific narrative in real time The term “scientific narrative” refers to the comprehensive communication strategy to position a therapy and sets forth the quintessence of the mission and vision of a particular therapy. It encompasses all attributes of the therapy from scientific data and health economic arguments to clinical practice …

Does Your Scientific Narrative Resonate in the Pharmaceutical Ecosystem? Read More »